Literature DB >> 9112058

Actual use of inhaled corticosteroids and risk of hospitalisation: a case-control study.

E van Ganse1, I Hubloue, W Vincken, H G Leufkens, J Gregoire, P Ernst.   

Abstract

BACKGROUND: The relationship between therapy and adverse outcome in asthma is debated especially for naturally occurring situations. This is due in part to insufficient information regarding actual use of medications.
OBJECTIVE: This study was conducted to clarify the relationship between actual intake of anti-asthma drugs and asthma hospitalisation, considered as an outcome.
METHODS: A case-control study was performed. Patients hospitalised for an asthma exacerbation were matched to community controls identified in surrounding general practices. Patients were questioned to identify prior use of anti-asthma medications, level of use of inhaled corticosteroids and attitude towards therapy.
RESULTS: Twenty-three cases and 31 matched controls were interviewed. Cases tended to have more severe asthma than controls, as judged by more frequent use of oral corticosteroids. Cases tended to make more frequent use of oral xanthines and inhaled anticholinergics, but the proportion of patients using inhaled beta 2-adrenoceptor agonists and inhaled corticosteroids was similar in both groups. Use of lower doses of inhaled corticosteroids was associated with an increased risk of hospitalisation, while higher dosage was associated with decreased risk. Cases and controls differed as to their answers to a questionnaire concerning attitudes: cases expressed less interest in optimal usage of inhaled corticosteroids than controls; they also expressed more confidence in inhaled beta 2-agonists. When both risks were combined, overconfidence in beta 2-agonists and suboptimal use of inhaled steroids, the relationship with hospitalisation was significant (OR 5.5, 95% CI 1.1; 26.1).
CONCLUSION: The results suggest that patients' attitudes to inhaled corticosteroids and actual consumption of these medications are directly related to adverse outcome in asthma.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9112058     DOI: 10.1007/s002280050229

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  6 in total

Review 1.  The paradox of adult asthma control: "who's in control anyway?".

Authors:  Rick Hodder
Journal:  Can Respir J       Date:  2007 May-Jun       Impact factor: 2.409

Review 2.  Montelukast: a review of its therapeutic potential in persistent asthma.

Authors:  B Jarvis; A Markham
Journal:  Drugs       Date:  2000-04       Impact factor: 9.546

Review 3.  Inhaled fluticasone propionate: a review of its therapeutic efficacy at dosages < or = 500 microg/day in adults and adolescents with mild to moderate asthma.

Authors:  B Jarvis; D Faulds
Journal:  Drugs       Date:  1999-05       Impact factor: 9.546

Review 4.  Inhaled mometasone furoate: a review of its use in adults and adolescents with persistent asthma.

Authors:  M Sharpe; B Jarvis
Journal:  Drugs       Date:  2001       Impact factor: 9.546

5.  Treatment compliance, passive smoking, and asthma control: a three year cohort study.

Authors:  D Soussan; R Liard; M Zureik; D Touron; Y Rogeaux; F Neukirch
Journal:  Arch Dis Child       Date:  2003-03       Impact factor: 3.791

Review 6.  A review of the effects of medication delivery systems on treatment adherence in children with asthma.

Authors:  Robert C Cohn
Journal:  Curr Ther Res Clin Exp       Date:  2003-01
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.